TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19818574

Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 80

Group type: COMPARATOR
Intervention: nPSV
Number of subjects: 80
Study: 17464905

Group type: EXPERIMENTAL
Intervention: Coping with stress training (SBT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (waiting)
Number of subjects: 30
Study: 17823517

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied twice daily for 7 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 7 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 14707556

Group type: EXPERIMENTAL
Intervention: 546C88
Number of subjects: 797

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 797
Study: 11151289

Group type: EXPERIMENTAL
Intervention: Stress management training program (cognitive-restructuring and problem-solving strategies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8960377

Group type: EXPERIMENTAL
Intervention: Beraprost sodium 20 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beraprost sodium 40 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beraprost sodium 60 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (20-60 micrograms)
Number of subjects: 12
Study: 1534729

Group type: EXPERIMENTAL
Intervention: Lactase treatment (9900 FCC units, 3 chewable tablets)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lactase treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 6143968

Group type: EXPERIMENTAL
Intervention: Recombinant DNA leucocyte interferon A
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30784673

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 2067

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 2067
Study: 30077803

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT) skills group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy (PPT) group
Number of subjects: 54

Group type: COMPARATOR
Intervention: DBT
Number of subjects: 54

Group type: COMPARATOR
Intervention: PPT
Number of subjects: 54
Study: 27017331

Group type: EXPERIMENTAL
Intervention: Olfactory training for 16 weeks
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Olfactory training for 56 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no olfactory training)
Number of subjects: 111
Study: 24812071

Group type: EXPERIMENTAL
Intervention: Integrated intervention including monthly breastfeeding learning sessions, weekly text and voice messages, and participant-generated songs and dramas.
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control arm continued with the regular microcredit program.
Number of subjects: 390
Study: 22250885

Group type: EXPERIMENTAL
Intervention: Self‐administered computer therapy targeting whole word production with error reduction strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visuospatial sham computer program
Number of subjects: 0
Study: 19281013

Group type: EXPERIMENTAL
Intervention: Back-rotation traction manipulation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine treatment (acupuncture, obturation, needle-knife)
Number of subjects: 86
Study: 17229323

Group type: COMPARATOR
Intervention: 0 g alcohol (control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 15 g alcohol (one drink)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 30 g alcohol (two drinks)
Number of subjects: 51
Study: 16333887

Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy with adjuvant propranolol (40 mg tds)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Injection sclerotherapy only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy with adjuvant propranolol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 12223437

Group type: EXPERIMENTAL
Intervention: High-fiber group (13.5 g/day)
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Low-fiber group (2.0 g/day)
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Supplemental fiber intake greater than 11.0 g/day
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Total fiber intake greater than 30.3 g/day
Number of subjects: 1208
Study: 9653495

Group type: EXPERIMENTAL
Intervention: FU-Plus-LV (400 mg/m2/day FU + 20 mg/m2/day LV for 5 days)
Number of subjects: 309

Group type: COMPARATOR
Intervention: FU Alone (400 mg/m2/day FU)
Number of subjects: 309
Study: 7858400

Group type: EXPERIMENTAL
Intervention: Propofol infusion rate < 6.0 mg.kg‐1.h‐1
Number of subjects: 400

Group type: COMPARATOR
Intervention: Propofol infusion rate > 6.0 mg.kg‐1.h‐1
Number of subjects: 400
Study: 2915887

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil, adriamycin, and cyclophosphamide (FAC)
Number of subjects: 94

Group type: COMPARATOR
Intervention: 5‐fluorouracil, epirubicin, and cyclophosphamide (FEC)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: FAC
Number of subjects: 94

Group type: COMPARATOR
Intervention: FEC
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: FAC and FEC
Number of subjects: 94
Study: 1149786

Group type: EXPERIMENTAL
Intervention: Phlorizin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (lactase deficient subjects)
Number of subjects: 2
Study: 31977699

Group type: EXPERIMENTAL
Intervention: Microneedling therapy
Number of subjects: 14
Study: 31033013

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg) in dim light (10 lux)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg) in bright light (2000 lux)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo in dim light (10 lux)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo in bright light (2000 lux)
Number of subjects: 10
Study: 28760175

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Jogging
Number of subjects: 27

Group type: COMPARATOR
Intervention: Stretching (Control)
Number of subjects: 27
Study: 25640706

Group type: EXPERIMENTAL
Intervention: Fluid boluses of 0.9% saline
Number of subjects: 3170

Group type: EXPERIMENTAL
Intervention: Fluid boluses of albumin
Number of subjects: 3170

Group type: EXPERIMENTAL
Intervention: Transfusion
Number of subjects: 3170

Group type: COMPARATOR
Intervention: Control group (no transfusion)
Number of subjects: 3170
Study: 24533998

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 1910

Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 1910
Study: 22459236

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 246

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 246
Study: 18930209

Group type: EXPERIMENTAL
Intervention: LUVO plus laparoscopic myomectomy (LUVO+LM)
Number of subjects: 131

Group type: COMPARATOR
Intervention: LUVO plus ultra-mini laparotomy (LUVO+UMLT-M)
Number of subjects: 131
Study: 17131072

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 46

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 46
Study: 15184278

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/d
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/d
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Duloxetine (various doses)
Number of subjects: 15
Study: 12583942

Group type: EXPERIMENTAL
Intervention: 50 microg salmeterol twice daily (n=372)
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: 500 microg fluticasone twice daily (n=374)
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: 50 microg salmeterol and 500 microg fluticasone twice daily (n=358)
Number of subjects: 1465

Group type: COMPARATOR
Intervention: Placebo (n=361)
Number of subjects: 1465
Study: 10561271

Group type: EXPERIMENTAL
Intervention: Expert radiologists' interpretations of CT scans
Number of subjects: 59
Study: 7532573

Group type: EXPERIMENTAL
Intervention: Non-verbal patterns
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Word and word-like letter strings
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Non-verbal stimuli
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Closed class words
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Phonological matching
Number of subjects: 9
Study: 1783346

Group type: EXPERIMENTAL
Intervention: Gelofalk (a combination of smectite, aluminium hydroxide, and magnesium hydroxide)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Aluminium hydroxide antacid (control)
Number of subjects: 97
Study: 7211892

Group type: EXPERIMENTAL
Intervention: 30 mg of medroxyprogesterone (MPG) daily for approximately one month
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 21
Study: 31398904

Group type: EXPERIMENTAL
Intervention: Dynamic stretching exercises three times per week for 6 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Static stretching exercises three times per week for 6 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no stretching protocol)
Number of subjects: 27
Study: 27571237

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide gel
Number of subjects: 27

Group type: COMPARATOR
Intervention: 35% hydrogen peroxide gel
Number of subjects: 27
Study: 26905220

Group type: EXPERIMENTAL
Intervention: BNP-guided heart failure treatment
Number of subjects: 258

Group type: COMPARATOR
Intervention: Routine heart failure treatment (Control)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Responders to BNP-guided therapy
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Non-responders to BNP-guided therapy
Number of subjects: 258
Study: 25213052

Group type: EXPERIMENTAL
Intervention: Lansoprazole treatment
Number of subjects: 110

Group type: COMPARATOR
Intervention: EBC pH measurement
Number of subjects: 110
Study: 21789654

Group type: EXPERIMENTAL
Intervention: Sutures with slow-absorbing material (PDS 2.0)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Tissue glue (Histoacryl)
Number of subjects: 264
Study: 19618317

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment for 8 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 10
Study: 17243866

Group type: EXPERIMENTAL
Intervention: Combined vitamins K(1) and D(3) plus calcium
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Vitamin K(1) (200 microg/day)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (10 microg or 400 IU) plus calcium (1000 mg/day)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 15331942

Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 209

Group type: COMPARATOR
Intervention: Citrate plus low-dose heparin
Number of subjects: 209
Study: 11978136

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids (100 to 200 mg/day in the initial phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine (mainly as maintenance treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combinations of corticosteroids with cytotoxic drugs (azathioprine, cyclophosphamide, chlorambucil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids with sulfa drugs (dapsone, clofazimine, minocycline, thalidomide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local application of granulocyte-macrophage colony-stimulating factor, intravenous immunoglobulins, plasmapheresis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin transplants (split-skin grafts or autologous keratinocyte grafts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical therapy with modern wound dressings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic antibacterial therapy
Number of subjects: 0
Study: 9212138

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia (n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia (n = 12)
Number of subjects: 23
Study: 8221837

Group type: EXPERIMENTAL
Intervention: TOPV produced by China
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TOPV produced by Yugoslavia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TOPV produced by Belgium
Number of subjects: 0
Study: 3114397

Group type: EXPERIMENTAL
Intervention: Postoperative TPN
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional fluid and electrolyte support
Number of subjects: 92
Study: 31832638

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole treatment (CTX-T)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No cotrimoxazole treatment (CTX-N)
Number of subjects: 63
Study: 29424609

Group type: EXPERIMENTAL
Intervention: HCC with incentive
Number of subjects: 82

Group type: COMPARATOR
Intervention: HCC without incentive
Number of subjects: 82

Group type: COMPARATOR
Intervention: LCC
Number of subjects: 82
Study: 25398661

Group type: EXPERIMENTAL
Intervention: 2.2-mm superior clear corneal incision (SCCI)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 1.8-mm superior clear corneal incision (SCCI)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control 3.2-mm superior clear corneal incision (SCCI)
Number of subjects: 151
Study: 24986744

Group type: EXPERIMENTAL
Intervention: IBCL seeds
Number of subjects: 140

Group type: COMPARATOR
Intervention: Loose seeds
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: IBCL seeds and Loose seeds
Number of subjects: 140
Study: 22074491

Group type: EXPERIMENTAL
Intervention: Self-esteem and health locus of control intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study: 19535429

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) (8 g oil/d)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Safflower oil (SAF) (8 g oil/d)
Number of subjects: 55
Study: 18089983

Group type: EXPERIMENTAL
Intervention: 10-session peer mentoring intervention
Number of subjects: 966

Group type: COMPARATOR
Intervention: 8-session video discussion intervention (control condition)
Number of subjects: 966
Study: 15223199

Group type: EXPERIMENTAL
Intervention: Transverse callosotomy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sagittal callosotomy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 11449087

Group type: EXPERIMENTAL
Intervention: Estrogen group (21 tablets with 20 microg of ethinyl‐estradiol and 150 mg of desogestrel for 21 days, followed by 2 placebo tablets and 5 ethinyl‐estradiol tablets of 10 microg each)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo group (21 tablets with 20 microg of ethinyl‐estradiol and 150 mg of desogestrel for 21 days, followed by 7 placebo tablets)
Number of subjects: 56
Study: 9749850

Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 672

Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 672
Study: 7839843

Group type: EXPERIMENTAL
Intervention: Cemented femoral components made of titanium alloy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no metallic implant)
Number of subjects: 19
Study: 2835245

Group type: EXPERIMENTAL
Intervention: Intravenous L-648,051 (35, 52.5, and 70 mg/5 min infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aerosolized L-648,051 (0.1 to 1.6 mg)
Number of subjects: 20
Study: 1677015

Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid antagonist)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 366803

Group type: EXPERIMENTAL
Intervention: O2
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CO2
Number of subjects: 3

Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 3
Study: 30895637

Group type: EXPERIMENTAL
Intervention: Intralesional application of medical grade honey (MGH)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study: 31511279

Group type: EXPERIMENTAL
Intervention: Oligosaccharide-sialic acid (OS) preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27687823

Group type: EXPERIMENTAL
Intervention: Exercise therapy group (EG) - home‐based progressive strength and aerobic training program for 12 months
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual care group (UCG) - received only oral and written instructions of exercises
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Exercise therapy group (EG)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 98
Study: 26112220

Group type: EXPERIMENTAL
Intervention: Self-Management Support (SMS) delivered by practice nurses
Number of subjects: 264

Group type: COMPARATOR
Intervention: Usual care provided by practice nurses
Number of subjects: 264
Study: 23303106

Group type: EXPERIMENTAL
Intervention: Foley bulb plus vaginal misoprostol
Number of subjects: 123

Group type: COMPARATOR
Intervention: Vaginal misoprostol alone
Number of subjects: 123
Study: 21332891

Group type: EXPERIMENTAL
Intervention: Lactobacillus sporogenes (Bacillus coagulans)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 148
Study: 19165529

Group type: EXPERIMENTAL
Intervention: MPH ER (10 mg/day to 60 mg/day)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study: 17130747

Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infant formula enriched in alpha-lactalbumin with higher GMP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infant formula enriched in alpha-lactalbumin with lower GMP
Number of subjects: 0
Study: 15123495

Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (UC) control condition
Number of subjects: 120
Study: 11433049

Group type: EXPERIMENTAL
Intervention: Motivational Intervention (MI)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Self-Help (SH)
Number of subjects: 291
Study: 9229881

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.1 mg/kg bolus followed by continuous infusion 0.1 mg/kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.2 mg/kg bolus followed by continuous infusion 0.2 mg/kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.3 mg/kg bolus followed by continuous infusion 0.3 mg/kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectal application of 100 mg indomethacin
Number of subjects: 0
Study: 8387576

Group type: COMPARATOR
Intervention: Standard-dose cisplatin (SDCP) 50 mg/m2 days 1 and 8 on a 28-day cycle for eight cycles
Number of subjects: 356

Group type: COMPARATOR
Intervention: High-dose cisplatin (HDCP) 100 mg/m2 days 1 and 8 for four cycles
Number of subjects: 356

Group type: COMPARATOR
Intervention: High-dose cisplatin plus mitomycin (HDCP-M) 8 mg/m2 day 1
Number of subjects: 356
Study: 2893636

Group type: EXPERIMENTAL
Intervention: Ketanserin (mean daily dose 77 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nifedipine (mean daily dose 62 mg)
Number of subjects: 24
Study: 31722679

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia with ropivacaine wound infiltration and intravenous flurbiprofen axetil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28568974

Group type: EXPERIMENTAL
Intervention: 1600 mg mesalazine tablets (3.2 g oral mesalazine, administered as two 1600 mg tablets once daily)
Number of subjects: 817

Group type: COMPARATOR
Intervention: 400 mg mesalazine tablets (4 tablets twice daily)
Number of subjects: 817
Study: 26571066

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-Velpatasvir
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 23219177

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 692

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 692
Study: 22011376

Group type: EXPERIMENTAL
Intervention: Potassium hydroxide (KOH) 10%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potassium hydroxide (KOH) 15%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potassium hydroxide (KOH) 10% and 15%
Number of subjects: 0
Study: 18695660

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions (GTs)
Number of subjects: 74
Study: 17699358

Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 13

Group type: COMPARATOR
Intervention: Lemonade
Number of subjects: 13

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 13
Study: 12133554

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10434263

Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relapsers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 7755647

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study: 2267246

Group type: EXPERIMENTAL
Intervention: Patient-nurse contract
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group orientation to unit routines
Number of subjects: 41
Study: 7241435

Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 25 1/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 80 1/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 25 1/min with 20% vital capacity
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 25 1/min with 50% vital capacity
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 25 1/min with 80% vital capacity
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 80 1/min with 20% vital capacity
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 80 1/min with 50% vital capacity
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 80 1/min with 80% vital capacity
Number of subjects: 8
Study: 31678536

Group type: EXPERIMENTAL
Intervention: Double-targeted DNA vaccine of Vibrio mimicus
Number of subjects: 0